Trials / Recruiting
RecruitingNCT06637332
Daptomycin vs. Vancomycin for the Treatment of Methicillin Resistant S. Aureus Bacteremia
DAPTO-SNAP: Daptomycin vs. Vancomycin for the Treatment of Methicillin Resistant S. Aureus Bacteremia
- Status
- Recruiting
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 300 (estimated)
- Sponsor
- Todd C. Lee MD MPH FIDSA · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is an open label randomized controlled trial for patients with methicillin resistant S. aureus (MRSA) bloodstream infection which will directly compare the two most commonly used therapies, vancomycin and daptomycin. This study is an approved sub-study of The Staphylococcus aureus Network Adaptive Platform (SNAP) trial (NCT05137119)
Conditions
- Staphylococcus Aureus Septicemia
- Staphylococcus Aureus Bacteremia
- S. Aureus Bacteremia
- S. Aureus Bloodstream Infection
- Staphylococcus Aureus Endocarditis
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Daptomycin for Injection | Daptomycin given by injection at a dose determined by the treating team but not to be less than 6mg/kg |
| DRUG | Vancomycin (IV) | Vancomycin by injection to be given at a dose selected by the treating team to achieve a desired trough level or AUC-based target, as determined by local standards of care |
Timeline
- Start date
- 2024-11-14
- Primary completion
- 2027-01-01
- Completion
- 2027-11-01
- First posted
- 2024-10-15
- Last updated
- 2026-02-25
Locations
14 sites across 2 countries: Australia, Canada
Source: ClinicalTrials.gov record NCT06637332. Inclusion in this directory is not an endorsement.